A high-throughput radioactivity-based assay for screening SARS-CoV-2 nsp10-nsp16 complex
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
Frequent outbreaks of novel coronaviruses (CoVs), highlighted by the current SARS-CoV-2 pandemic, necessitate the development of therapeutics that could be easily and effectively administered world-wide. The conserved mRNA-capping process enables CoVs to evade their host immune system and is a target for antiviral development. Nonstructural protein (nsp) 16 in complex with nsp10 catalyzes the final step of coronaviral mRNA-capping through its 2’-O-methylation activity. Like other methyltransferases, SARS-CoV-2 nsp10-nsp16 complex is druggable. However, the availability of an optimized assay for high-throughput screening (HTS) is an unmet need. Here, we report the development of a radioactivity-based assay for methyltransferase activity of nsp10-nsp16 complex in a 384-well format, and kinetic characterization, and optimization of the assay for HTS (Z′-factor: 0.83). Considering the high conservation of nsp16 across known CoV species, the potential inhibitors targeting SARS-CoV-2 nsp10-nsp16 complex may also be effective against other emerging pathogenic CoVs.
Article activity feed
-
SciScore for 10.1101/2021.02.03.429625: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources The kinetic parameters were calculated using Michaelis-Menten equation by GraphPad Software. GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Sequence Analysis: Nsp16 protein sequences were taken from the CoV ORF1ab sequences accessible through UniProt database. UniProtsuggested: (UniProtKB, RRID:SCR_004426)The nsp16 sequences were aligned using Clustal Omega 33, and sequence similarities and secondary structure features were rendered by ESPript Version 3.0 34. Clustal Omegasugge…SciScore for 10.1101/2021.02.03.429625: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources The kinetic parameters were calculated using Michaelis-Menten equation by GraphPad Software. GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Sequence Analysis: Nsp16 protein sequences were taken from the CoV ORF1ab sequences accessible through UniProt database. UniProtsuggested: (UniProtKB, RRID:SCR_004426)The nsp16 sequences were aligned using Clustal Omega 33, and sequence similarities and secondary structure features were rendered by ESPript Version 3.0 34. Clustal Omegasuggested: (Clustal Omega, RRID:SCR_001591)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
